Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Cash from Financing Activities for 3 consecutive years, with $64000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Cash from Financing Activities fell 76.3% year-over-year to $64000.0, compared with a TTM value of $729000.0 through Dec 2021, down 99.66%, and an annual FY2024 reading of $25.5 million, down 64.48% over the prior year.
  • Cash from Financing Activities was $64000.0 for Q3 2021 at Black Diamond Therapeutics, down from $184000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $213.8 million in Q1 2020 and bottomed at -$70000.0 in Q2 2019.
  • Average Cash from Financing Activities over 3 years is $38.2 million, with a median of $481000.0 recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 76.3% in 2021, while the deepest fall reached 99.78% in 2021.
  • Year by year, Cash from Financing Activities stood at $83.5 million in 2019, then tumbled by 99.01% to $830000.0 in 2020, then crashed by 92.29% to $64000.0 in 2021.
  • Business Quant data shows Cash from Financing Activities for BDTX at $64000.0 in Q3 2021, $184000.0 in Q2 2021, and $481000.0 in Q1 2021.